Increasing the antitumor effect of an EpCAM-targeting fusion toxin by facile click PEgylation

Molecular Cancer Therapeutics

Volumn 13, Issue 2, 2014, Pages 375-385

  Simon, Manuel ^a,b,c   Stefan, Nikolas ^b   Borsig, Lubor ^b   Pleuckthun, Andreas ^b   Zangemeister Wittke, Uwe ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c Discovery Oncology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BACTERIAL TOXIN; CELL ADHESION MOLECULE; EPCAM PROTEIN, HUMAN; EXOTOXIN; HYBRID PROTEIN; MACROGOL DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TOXA PROTEIN, PSEUDOMONAS AERUGINOSA; TUMOR ANTIGEN; VIRULENCE FACTOR;

ANIMAL; CELL SURVIVAL; CHEMISTRY; CLICK CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENETICS; HT 29 CELL LINE; HUMAN; MCF 7 CELL LINE; METABOLISM; NEOPLASMS; NUDE MOUSE; PATHOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; SURFACE PLASMON RESONANCE; TUMOR CELL LINE; TUMOR VOLUME;

ADP RIBOSE TRANSFERASES; ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BACTERIAL TOXINS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL SURVIVAL; CLICK CHEMISTRY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EXOTOXINS; FEMALE; HT29 CELLS; HUMANS; MCF-7 CELLS; MICE, NUDE; NEOPLASMS; POLYETHYLENE GLYCOLS; RECOMBINANT FUSION PROTEINS; SURFACE PLASMON RESONANCE; TUMOR BURDEN; VIRULENCE FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84894219315     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0523     Document Type: Article

References (51)

1. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 2006;5:147-59
2. Weiner LM, Murray JC, Shuptrine CW. Antibody-based immunotherapy of cancer. Cell 2012;148:1081-4
3. Adair JR, Howard PW, Hartley JA, Williams DG, Chester KA. Antibodydrug conjugates-A perfect synergy. Expert Opin Biol Ther 2012;12: 1191-206
4. Binz HK, Amstutz P, Pleuckthun A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 2005;23:1257-68
5. Boersma YL, Pleuckthun A. DARPins and other repeat protein scaffolds: advances in engineering and applications. Curr Opin Biotechnol 2011;22:849-57
6. Teicher BA, Chari RV. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res 2011;17:6389-97
7. Binz HK, Stumpp MT, Forrer P, Amstutz P, Pleuckthun A. Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J Mol Biol 2003;332:489-503
8. Tamaskovic R, Simon M, Stefan N, Schwill M, Pleuckthun A. Designed ankyrin repeat proteins (DARPins) from research to therapy. Methods Enzymol 2011;503:101-34
9. Simon M, Zangemeister-Wittke U, Pleuckthun A. Facile double- functionalization of designed ankyrin repeat proteins using click and thiol chemistries. Bioconj Chem 2012;23:279-86
10. Simon M, Frey R, Zangemeister-Wittke U, Pleuckthun A. Orthogonal Assembly of a Designed Ankyrin Repeat Protein-cytotoxin conjugate with a clickable serum albumin module for half-life extension. Bioconjug Chem 2013;24:1955-66
11. Steiner D, Forrer P, Pleuckthun A. Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display. J Mol Biol 2008;382:1211-27
12. Zahnd C, Pecorari F, Straumann N, Wyler E, Pleuckthun A. Selection and characterization of Her2-binding designed ankyrin repeat proteins. J Biol Chem 2006;281:35167-75
13. Stefan N, Martin-Killias P, Wyss-Stoeckle S, Honegger A, Zangemeister-Wittke U, Pleuckthun A. DARPins recognizing the tumorassociated antigen EpCAM selected by phage and ribosome display and engineered for multivalency. J Mol Biol 2011;413: 826-43
14. Went P, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, et al. Frequent EpCAM protein expression in human carcinomas. Hum Pathol 2004;35:122-8
15. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, et al. Nuclear signalling by tumour-Associated antigen EpCAM. Nat Cell Biol 2009;11:162-71
16. Baeuerle PA, Gires O. EpCAM (CD326) finding its role in cancer. Br J Cancer 2007;96:417-23
17. van der Gun BTF, Melchers LJ, Ruiters MHJ, Leij LFMH, McLaughlin PMJ, Rots MG. EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 2010;31:1913-21
18. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10:6897-904
19. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008;8:329-40
20. Oberneder R, Weckermann D, Ebner B, Quadt C, Kirchinger P, RaumT, et al. A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. Eur J Cancer 2006;42:2530-8
21. Marschner N, Ruettinger D, Zugmaier G, Nemere G, Lehmann J, Obrist P, et al. Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy. Urol Int 2010;85:386-95
22. Moldenhauer G, Salnikov AV, Leuttgau S, Herr I, Anderl J, Faulstich H. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. J Natl Cancer Inst 2012;104:622-34
23. Di Paolo C, Willuda J, Kubetzko S, Schubiger A, Stahel R, Zangemeister-Wittke U, et al. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Clin Cancer Res 2003;9:2837-48
24. Winkler J, Martin-Killias P, Pleuckthun A, Zangemeister-Wittke U. EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins. Mol Cancer Ther 2009;8:2674-83
25. Martin-Killias P, Stefan N, Rothschild S, Pleuckthun A, Zangemeister-Wittke U. A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity. Clin Cancer Res 2011;17:100-10
26. Simon M, Stefan N, Pleuckthun A, Zangemeister-Wittke U. Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy. Expert Opin Drug Deliv 2013;10:451-68
27. Weldon JE, Pastan I. A guide to taming a toxin -recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS 2011;278:4683-700
28. Pastan I. Immunotoxins containing Pseudomonas exotoxin A: a short history. Cancer Immunol Immunother 2003;52:338-41
29. FitzGerald DJ, Wayne AS, Kreitman RJ, Pastan I. Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res 2011;71:6300-9
30. Zielinski R, Lyakhov I, Hassan M, Kuban M, Shafer-Weaver K, Gandjbakhche A, et al. HER2-Affitoxin: a potent therapeutic agent for the treatment of HER2-overexpressing tumors. Clin Cancer Res 2011;17: 5071-81
31. Tsutsumi Y, Onda M, Nagata S, Lee B, Kreitman RJ, Pastan I. Sitespecific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc Natl Acad Sci U S A 2000;97:8548-53
32. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005;10:1451-8
33. Caliceti P, Veronese F. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Del Rev 2003; 55:1261-77
34. Alconcel SNS, Baas AS, Maynard HD. FDA-Approved poly(ethylene glycol)-protein conjugate drugs. Polym Chem 2011;2:1442-8
35. Kurfeurst MM. Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anal Biochem 1992;200: 244-8
36. Yang K, Basu A, Wang M, Chintala R, Hsieh M-C, Liu S, et al. Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation. Protein Eng 2003; 16:761-70
37. Kubetzko S, Sarkar CA, Pleuckthun A. Protein PEGylation decreases observed target association rates via a dual blocking mechanism. Mol Pharmacol 2005;68:1439-54
38. Veronese FM. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 2001;22:405-17
39. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Controlled Release 2000;65:271-84
40. Harris JM, Chess RB. Effect of PEGylation on pharmaceuticals. Nat Rev Drug Discov 2003;2:214-21
41. Bailon P, Won C-Y. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv 2009;6:1-16
42. Filpula D, Yang K, Basu A, Hassan R, Xiang L, Zhang Z, et al. Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice. Bioconj Chem 2007;18:773-84
43. Shen B-Q, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibodydrug conjugates. Nat Biotechnol 2012;30:184-9
44. Onda M, Vincent JJ, Lee B, Pastan I. Mutants of immunotoxin anti-Tac (dsFv)-PE38 with variable number of lysine residues as candidates for site-specific chemical modification. Bioconj Chem 2003;14: 480-7
45. Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. J Cell Biol 2010;188:759-68
46. Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol 2011;22:868-76
47. PirieCM, Hackel BJ, Rosenblum MG, Wittrup KD.Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties. J Biol Chem 2011;286:4165-72
48. Fontana A, Spolaore B, Mero A, Veronese FM. Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase. Adv Drug Del Rev 2008;60:13-28
49. Molineux G. PEGylation: engineering improved pharmaceuticals for enhanced therapy. Cancer Treat Rev 2002;28:13-6
50. Wolf P, Elseasser-Beile U. Pseudomonas exotoxin A: from virulence factor to anti-cancer agent. Int J Med Microbiol 2009;299:161-76
51. Hage El T, Lorin S, Decottignies P, Djavaheri-Mergny M, Authier F. Proteolysis of Pseudomonas exotoxin A within hepatic endosomes by cathepsins B and D produces fragments displaying in vitro ADPribosylating and apoptotic effects. FEBS J 2010;277:3735-49.